在瘤发生过程中,线粒体代谢的多方面的调节
Rajendiran Keerthiga1, Yafang Xie2, De-Sheng Pei3
1College of Pharmaceutical Science, Southwest University, Chongqing, 400716, China; Department of Computational Biology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Thandalam, Chennai 602105, Tamil Nadu, India.
Mitochondrion
|November 6, 2024
概括
线粒体新陈代谢的变化驱动癌症的发展. 针对瘤线粒体中的这些代谢变化,为癌症预防和治疗提供了新的途径.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- 线粒体代谢对于正常细胞功能至关重要.
- 异常的线粒体代谢是癌症的标志,推动恶性转变.
- 由线粒体产生的代代谢体表明瘤存在并维持癌症表型.
研究的目的:
- 审查线粒体代谢在瘤发生中的多方面的作用.
- 阐明线粒体新陈代谢如何促进癌症的标志.
- 突出针对瘤线粒体的治疗策略.
主要方法:
- 文学综述综合了关于线粒体代谢和癌症的当前研究.
- 分析线粒体功能与癌症进展之间的相互作用.
- 讨论由线粒体变化影响的特定癌症特征.
主要成果:
- 线粒体代谢通过生物能量和生物合成途径推动癌症的进展.
- 线粒体功能,如调节,动力学和上皮层-介质细胞过渡在癌症中至关重要.
- 瘤微环境信号与线粒体新陈代谢同步,促进瘤的启动和生长.
结论:
- 异常的线粒体代谢是瘤发生的关键驱动因素.
- 了解这些代谢变化,可以了解癌症的发展.
- 向瘤线粒体是癌症治疗和预防的有希望的策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
Mitochondrial Membranes
9.0K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
9.0K
Mitochondria
11.2K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
11.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


